Triple therapy superior to dual therapy in HCV
As reported in Mayo Clinic Proceedings, treatment of hepatitis C virus-infected patients with triple therapy (pegylated-interferon, ribavirin, and teleprevir) is more effective than dual therapy (pegylated-interferon and ribavirin). Specifically, a sustained virologic response was achieved in 51% of treatment-naïve patients, 67% of patients with a prior non-response and 56% of patients with a prior relapse of patients treated with triple therapy compared to 37%, 11%, and 27% of patients treated with dual therapy, respectively.
Tobacco and alcohol use significantly increase risk for ESCC
Based on a meta-analysis (n=5 studies) reported in the American Journal of Gastroenterology, the combined use of tobacco and alcohol increased the risk for esophageal squamous cell carcinoma (OR=3.28) compared with non-users; users of tobacco or alcohol alone had a 20%-30% increased risk of esophageal squamous cell carcinoma compared to non-users.
Predictors of poor coronary collateral circulation in stable CAD
As reported in Angiology, the fasting blood glucose and serum uric acid levels and the white blood cell count were higher in patients with stable CAD (n=480) and associated with poor coronary collateral circulation.